LOXO-101 (BioDeep_00000795846)
代谢物信息卡片
化学式: C21H22F2N6O2 (428.1772216)
中文名称: 拉罗替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F
InChI: InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155765 - TRK Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11137
- PubChem: 46188928
- DrugBank: DB14723
- ChEMBL: CHEMBL3889654
- CAS: 1223403-58-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zuqin Wang, Jie Wang, Yongjin Wang, Shuang Xiang, Xiaojuan Song, Zhengchao Tu, Yang Zhou, Zhi-Min Zhang, Zhang Zhang, Ke Ding, Xiaoyun Lu. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Journal of medicinal chemistry.
2022 04; 65(8):6325-6337. doi:
10.1021/acs.jmedchem.2c00308. [PMID: 35426680] - Christian Rolfo, Alexander Drilon, David Hong, Caroline McCoach, Afshin Dowlati, Jessica J Lin, Alessandro Russo, Alison M Schram, Stephen V Liu, Jorge J Nieva, Timmy Nguyen, Shahrooz Eshaghian, Michael Morse, Scott Gettinger, Mohammad Mobayed, Sarah Goldberg, Emilio Araujo-Mino, Neelima Vidula, Aditya Bardia, Janakiraman Subramanian, Deepa Sashital, Thomas Stinchcombe, Lesli Kiedrowski, Kristin Price, David R Gandara. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
British journal of cancer.
2022 02; 126(3):514-520. doi:
10.1038/s41416-021-01536-1. [PMID: 34480094] - Yaogeng Wang, Rolf W Sparidans, Jing Wang, Wenlong Li, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2022 Jan; 170(?):197-207. doi:
10.1016/j.ejpb.2021.12.007. [PMID: 34952136] - Maria Carter-Febres, Netta Schneller, Douglas Fair, David Solomon, Arie Perry, Angshumoy Roy, Luke Linscott, Mouied Alashari, John R Kestle, Carol S Bruggers. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
Journal of pediatric hematology/oncology.
2021 Oct; 43(7):e987-e990. doi:
10.1097/mph.0000000000001983. [PMID: 33093355] - Anisley Valenciaga, O Hans Iwenofu, Gabriel Tinoco. Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.
Journal of the National Comprehensive Cancer Network : JNCCN.
2021 07; 19(7):775-779. doi:
10.6004/jnccn.2021.7039. [PMID: 34340207] - Ross Mangum, Jacquelyn Reuther, Kelsey C Bertrand, Raghu Chandramohan, Marcia K Kukreja, Arnold C Paulino, Donna Muzny, Jianhong Hu, Richard A Gibbs, Daniel J Curry, Fatema Malbari, Murali M Chintagumpala, Adekunle M Adesina, Kevin E Fisher, Stephen C Mack, Sharon E Plon, Angshumoy Roy, D Williams Parsons, Frank Y Lin. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling.
JCO precision oncology.
2021; 5(?):. doi:
10.1200/po.20.00375. [PMID: 34651095] - Yunxin Duan, Jie Wang, Sihua Zhu, Zheng-Chao Tu, Zhang Zhang, Shingpan Chan, Ke Ding. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
European journal of medicinal chemistry.
2020 Oct; 203(?):112552. doi:
10.1016/j.ejmech.2020.112552. [PMID: 32702585] - Yaogeng Wang, Rolf W Sparidans, Wenlong Li, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.
British journal of pharmacology.
2020 07; 177(13):3060-3074. doi:
10.1111/bph.15034. [PMID: 32087611] - Harsha K Tripathy, S V Nair Manju, Ashok Zakkula, Ram Murthi Bestha, Sreekanth Dittakavi, Ramesh Mullangi. Validated HPLC Method for Quantification of a Novel Trk Inhibitor, Larotrectinib in Mice Plasma: Application to a Pharmacokinetic Study.
Drug research.
2020 Feb; 70(2-03):101-106. doi:
10.1055/a-1071-0849. [PMID: 31931548] - Shengyang Cui, Yongjin Wang, Yuting Wang, Xia Tang, Xiaomei Ren, Lei Zhang, Yong Xu, Zhang Zhang, Zhi-Min Zhang, Xiaoyun Lu, Ke Ding. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.
European journal of medicinal chemistry.
2019 Oct; 179(?):470-482. doi:
10.1016/j.ejmech.2019.06.064. [PMID: 31271959] - Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. NTRK fusion-positive cancers and TRK inhibitor therapy.
Nature reviews. Clinical oncology.
2018 12; 15(12):731-747. doi:
10.1038/s41571-018-0113-0. [PMID: 30333516] - Rolf W Sparidans, Yaogeng Wang, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2018 Dec; 1102-1103(?):167-172. doi:
10.1016/j.jchromb.2018.10.023. [PMID: 30396050] - Hadeel Halalsheh, Mary Beth McCarville, Michael Neel, Mark Reynolds, Michael C Cox, Alberto S Pappo. Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.
Pediatric blood & cancer.
2018 10; 65(10):e27271. doi:
10.1002/pbc.27271. [PMID: 29893456] - Robert C Doebele, Lara E Davis, Aria Vaishnavi, Anh T Le, Adriana Estrada-Bernal, Stephen Keysar, Antonio Jimeno, Marileila Varella-Garcia, Dara L Aisner, Yali Li, Philip J Stephens, Deborah Morosini, Brian B Tuch, Michele Fernandes, Nisha Nanda, Jennifer A Low. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Cancer discovery.
2015 Oct; 5(10):1049-57. doi:
10.1158/2159-8290.cd-15-0443. [PMID: 26216294]